DALLAS, Dec. 5, 2005 (PRIMEZONE) -- John Pentony, Publisher of StockGuru.com, announced today that the web site has initiated Profile Coverage of Chembio Diagnostics, Inc. (OTCBB:CEMI). Chembio was founded as a research organization in 1984. In 1995 it introduced its initial line of internally developed rapid diagnostic tests. These products, principally fertility tests, have become commodity products sold in a mature retail market. They have provided revenue to build a body of expertise in the development and manufacture of more proprietary rapid diagnostic tests. The Company possesses expertise in the development and manufacturing of rapid test products for various infectious diseases, including HIV, Tuberculosis and Chagas Disease.
To view the StockGuru Profile for Chembio Diagnostics, please visit: http://www.stockguru.com/profiles/cemi/
Last week StockGuru interviewed Lawrence Siebert of Chembio Diagnostics. To listen to that interview, please visit: http://www.stockguru.com/profiles/cemi/interview.php
About Chembio Diagnostics
Chembio Diagnostics, Inc. possesses expertise in the development and manufacturing of rapid test products for various infectious diseases, including HIV, Tuberculosis and Chagas Disease. References to Chembio Diagnostics, Inc. may actually refer to Chembio Diagnostic Systems, Inc.; the 100% owned subsidiary of Chembio Diagnostics, Inc. Chembio is located at 3661 Horseblock Road, Medford, NY 11763.
About StockGuru.com
StockGuru.com features daily alerts going out three times daily to members. To join our email alert list, please visit: http://www.stockguru.com/stocks.htm
To feature your publicly traded company in our alerts, or to discuss our complete services, please contact: John Pentony at (469) 252-3031 or email publisher@stockguru.com. We offer a variety of services including profiling publicly traded companies on our web site, we do interviews with CEOs or other key executives on our web site, and we have our financial writers cover our companies.
Forward-Looking Statements
Statements contained herein that are not historical facts may be forward-looking statements within the meaning of the Securities Act of 1933, as amended. Forward-looking statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to Chembio's ability to obtain additional financing and the demand for Chembio's products. Chembio undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in Chembio's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact Chembio's success are more fully disclosed in Chembio's most recent public filings with the U.S. Securities and Exchange Commission.
Disclosure: Pentony Enterprises LLC was compensated $9,000 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.